Antioxidant Supplements for Cystic Fibrosis

Recruiting in Palo Alto (17 mi)

Overseen byPaula Rodriguez Miguelez, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Recruiting

Sponsor: Virginia Commonwealth University

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing if antioxidant supplements can help people with cystic fibrosis (CF) exercise better. People with CF often struggle with exercise, which can lead to more hospital visits. Antioxidants might help by protecting their cells from damage, making it easier for them to stay active. Glutathione, an antioxidant, has shown potential in improving lung function and reducing oxidative stress in cystic fibrosis patients.

Research Team

Paula Rodriguez Miguelez, PhD

Principal Investigator

Virginia Commonwealth University

Eligibility Criteria

This trial is for adults over 18 with Cystic Fibrosis who can perform lung function tests and have an FEV1 percent predicted above 40%. They must not be current smokers, pregnant, or nursing, and should be clinically stable without recent exacerbations or heart disease.

Inclusion Criteria

I have been medically stable for the last 4 weeks.

You may or may not have diabetes related to cystic fibrosis.

I have been diagnosed with cystic fibrosis.

See 6 more

Exclusion Criteria

I have not had a fever or flu-like illness in the last 4 weeks.

I have been diagnosed with heart disease.

Patients with B. Cepacia infection.

See 7 more

Treatment Details

Interventions

NR (Antioxidant Supplement)
Placebo (Behavioural Intervention)
Resveratrol (Antioxidant Supplement)

Trial OverviewThe study is testing the effects of antioxidant supplements Resveratrol and NR on exercise intolerance in CF patients compared to a placebo. Participants will receive one of these treatments to see if it improves their ability to exercise.

Participant Groups

4Treatment groups

Experimental Treatment

Group I: B: Healthy ControlsExperimental Treatment2 Interventions

Healthy controls will be randomly assigned to NR or placebo

Group II: B: Cystic FibrosisExperimental Treatment2 Interventions

Patients with CF will be randomly assigned to NR or placebo.

Group III: A: Healthy ControlsExperimental Treatment2 Interventions

Healthy controls will be randomly assigned to resveratrol or placebo

Group IV: A: Cystic fibrosisExperimental Treatment2 Interventions

Patients with CF will be randomly assigned to resveratrol or placebo.